http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2330853-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1542e8802a0e6a7a8a7c6bd5627eb857 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2004-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de6f56ee2bddbe3ce58be6bf463e38aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50d1d8184e68008ba04d7f92607a9830 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf28a44c07d1cc8b879c56b1a2b76eac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4041bced3c88cc273746197fa8ea099 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fca38807bc998888c25d71285281db77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df821a9d3c4c67f7c5a690e44ed31b4d |
| publicationDate | 2008-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2330853-C2 |
| titleOfInvention | AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS |
| abstract | FIELD: chemistry. n SUBSTANCE: invention concerns compounds of the formula I and their pharmaceutically acceptable salts as factor Xa inhibitors, medicine based on them, as well as a method of their obtaining and application. In the general formula I R 0 is monocyclical or bicyclical 6-9-membered heterocyclyl selected out of the group of benzothiophenyl, pyridyl or monocyclical 5-membered heterocyclyl containing 1, 2 heteroatoms selected out of nitrogen or oxygen, where the mentioned heterocyclyl is monosubstituted by R8 and additionally substituted by monocyclical 5-membered heterocyclyl containing 1 heteroatom of sulfur, where heterocyclyl is monosubstituted by R8; R8 is a halogen or substructure , which is 6-membered partially unsaturated or aromatic cyclical group in the formula I, containing 1 nitrogen heteroatom, and which is substituted by 1 R23 group or oxogroup under a condition that the mentioned cyclical group is not a phenyl residuum; Q is a direct link, -(C 0 -C 2 )-alkylene-C(O)-NR 10 -, -(C 1 -C 6 )-alkylene; -R 1 is a hydrogen atom; R 2 is a direct link, V is a 6-membered cyclical residuum with 1 heteroatom selected out of nitrogen, where the mentioned cyclical residuum is unsubstituted, bicyclical 12-membered heterocyclyl with 1-2 heteroatom selected out of nitrogen, where the mentioned cyclical residuum is unsubstituted; G is a direct link; M a hydrogen atom, -(C 1 -C 8 )-alkyl where alkyl is unsubstituted; R3 is a hydrogen atom; R23 is a hydrogen atom, -(C 0 -C 4 )-alkylene -O-R19 (where R19 is a) hydrogen atom, b) -(C 1 -C 4 )-alkyl where alkyl is unsubstituted or monosubstituted by R13), -(C 0 -C 4 )-alkylene-C(O)-R 11 , -(C 0 -C 4 )-alkylene-C(O)-O-R 11 ; R11 and R12 can both or individually be hydrogen atom, -(C 1 -C 6 )-alkyl: -O-R 17 or R13 is -C(O)-O-R 10 ; R 10 and R 20 are hydrogen atoms or -(C 1 -C 6 )-alkyl independently from each other, R17 is -(C 1 -C 6 )-alkyl; and its pharmaceutically acceptable salts. n EFFECT: possible application in effecting blood coagulation, inflammation reaction or fibrinolysis, or in treatment and prophylactics of diseases caused by Xa factor, eg cardiovascular disorders, thromboembolic diseases or restenosis. n 11 cl, 1 tbl, 15 ex |
| priorityDate | 2003-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 541.